Search

Displaying all 5 results
DrugBest match

Ripretinib

go.drugbank.com/drugs/DB14840
ApprovedInvestigational

Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA ...

  1. Pathway

    Ripretinib Action Pathway

    smpdb.ca/view/SMP0126912
    Drug action

    Ripretinib is a kinase inhibitor primarily used to treat advanced gastrointestinal stromal tumor (GIST) that has not responded well to other kinase inhibitors like sunitinib and imatinib. … Ripretinib's mechanism of action involves inhibiting protein kinases, including both wild type and mutant forms of platelet-derived growth factor receptor A (PDGFRA) and KIT, which are implicated in the

    Drugs: Calcium · Ripretinib
  2. Pathway

    Ripretinib Predicted Metabolism Pathway

    smpdb.ca/view/SMP0174724
    Metabolic

    Metabolites of Ripretinib are predicted with biotransformer.

    Drugs: Mesoheme · Ripretinib
  3. Indication

    Advanced Gastrointestinal Stromal Tumor (GIST)

    go.drugbank.com/conditions/DBCOND0074706
    Drugs: Ripretinib
  4. Drug

    Avapritinib

    go.drugbank.com/drugs/DB15233
    ApprovedInvestigational

    [A189327] Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020.[L41464]